HOWL vs. ACIU, PBYI, VNDA, TELO, TSVT, ALDX, XERS, CDT, QURE, and FHTX
Should you be buying Werewolf Therapeutics stock or one of its competitors? The main competitors of Werewolf Therapeutics include AC Immune (ACIU), Puma Biotechnology (PBYI), Vanda Pharmaceuticals (VNDA), Telomir Pharmaceuticals (TELO), 2seventy bio (TSVT), Aldeyra Therapeutics (ALDX), Xeris Biopharma (XERS), Conduit Pharmaceuticals (CDT), uniQure (QURE), and Foghorn Therapeutics (FHTX). These companies are all part of the "pharmaceutical preparations" industry.
AC Immune (NASDAQ:ACIU) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, community ranking, profitability, earnings, risk, analyst recommendations and media sentiment.
Werewolf Therapeutics has higher revenue and earnings than AC Immune. Werewolf Therapeutics is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.
In the previous week, Werewolf Therapeutics had 1 more articles in the media than AC Immune. MarketBeat recorded 5 mentions for Werewolf Therapeutics and 4 mentions for AC Immune. Werewolf Therapeutics' average media sentiment score of 0.98 beat AC Immune's score of 0.58 indicating that AC Immune is being referred to more favorably in the media.
AC Immune has a net margin of 0.00% compared to AC Immune's net margin of -187.37%. AC Immune's return on equity of -32.25% beat Werewolf Therapeutics' return on equity.
AC Immune received 233 more outperform votes than Werewolf Therapeutics when rated by MarketBeat users. Likewise, 62.32% of users gave AC Immune an outperform vote while only 58.82% of users gave Werewolf Therapeutics an outperform vote.
AC Immune currently has a consensus price target of $16.00, suggesting a potential upside of 601.75%. Werewolf Therapeutics has a consensus price target of $11.50, suggesting a potential upside of 91.35%. Given Werewolf Therapeutics' higher probable upside, analysts plainly believe AC Immune is more favorable than Werewolf Therapeutics.
51.4% of AC Immune shares are owned by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are owned by institutional investors. 4.6% of AC Immune shares are owned by company insiders. Comparatively, 21.1% of Werewolf Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
AC Immune has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.Comparatively, Werewolf Therapeutics has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500.
Summary
AC Immune beats Werewolf Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Werewolf Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HOWL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HOWL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Werewolf Therapeutics Competitors List
Related Companies and Tools
